|
Recent Developments |
|
28-AUG-18
Panacea Biotec has entered into a tripartite agreement with Natco Pharma (Natco) and Breckenridge Pharmaceutical Inc. (Breckenridge) for the manufacture and supply of Azacitidine Injection for the U.S. market under Breckenridge's already-approved ANDA. Azacitidine is a generic equivalent of Vidaza??, which is marketed by Celgene Corporation, U.S.
12-MAR-18
Panacea Biotec announced the receipt of Establishment Inspection Report (EIR) ... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Mar-2016(12) | 31-Mar-2015(12) | 31-Mar-2014 (12) | | Net sales | 6353.40 | 6432.40 | 4671.40 | | Other Income | 255.60 | 280.60 | 116.40 | | Total Income | 6609.00 | 6713.00 | 4787.80 | | Cost of goods sold | 5521.10 | 6129.00 | 5975.20 | | OPBDIT | 1087.90 | 584.00 | -1187.40 | | PAT | 8.70 | -652.30 | -4.20 | | Gross Block | - | - | - | | Equity capital | 61.30 | 61.30 | 61.30 | | EPS (Rs.) | - | - | -0.07 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | NA | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 16.5 | 8.7 | -24.8 | | Net margin (% of OI) | 0.1 | -9.7 | -0.1 |
|
|
Detailed Financials
|
|
|
|
|
